An Observational Disease and Clinical Outcomes Registry of Patients With Lysosomal Acid Lipase (LAL) Deficiency
An Observational Disease and Clinical Outcomes Registry of Patients With Lysosomal Acid Lipase (LAL) Deficiency
This is an observational, multi-center, international disease registry designed to collect longitudinal data and create a knowledge base that will be utilized to improve the care and treatment of patients with LAL Deficiency. Participation in the Registry by both physicians and patients is voluntary.
Lysosomal Acid Lipase (LAL) Deficiency is a rare autosomal recessive lysosomal storage disorder (LSD) that is caused by a marked decrease of lysosomal acid lipase (LAL), the enzyme that breaks down cholesteryl esters and triglycerides in the lysosomes.
Lysosomal Acid Lipase Deficiency presenting in infants (historically called Wolman Disease) is a medical emergency with rapid disease progression over a period of weeks that is typically fatal within the first 6 months of life. More commonly, LAL Deficiency presents in children and adults and this presentation has been historically called Cholesteryl Ester Storage Disease (CESD). In general, data on the prevalence of LAL Deficiency are limited, and the overall prevalence of the disease in the population is unclear.
For all presentations, LAL Deficiency is associated with significant morbidity and mortality. Deficient LAL enzyme activity results in the lysosomal accumulation of cholesteryl esters and triglycerides. In the liver, this accumulation leads to hepatomegaly, increased hepatic fat content, transaminase elevation signaling chronic liver injury, and progression to fibrosis, cirrhosis, and complications of end stage liver disease. In the spleen, LAL Deficiency results in splenomegaly, anemia, and thrombocytopenia. Lipid accumulation in the intestinal wall leads to malabsorption and growth failure. Dyslipidemia is common with elevated low density lipoprotein (LDL) and triglycerides and low high density lipoprotein (HDL), associated with increased liver fat content and transaminase elevations. In addition to liver disease, patients with LAL Deficiency experience increased risk for cardiovascular disease and accelerated atherosclerosis.
The LAL Deficiency Registry is a global registry, established to help improve care for patients through improved understanding of the disease and long-term effectiveness of therapeutic interventions including sebelipase alfa.
As with other registries, which are becoming increasingly valuable for collecting information in large, heterogeneous, 'real world' populations, the LAL Deficiency Registry aims to provide evidence to help support patient care and inform clinical practice. This Registry is also being conducted, in part, to fulfill post-marketing commitments and requirements agreed to by the Sponsor as a condition for sebelipase alfa approval in the EU and the USA.
Patients must have a confirmed diagnosis of LAL Deficiency. An Informed Consent and Authorization must be obtained prior to patient enrollment where required under applicable laws and regulations, or a waiver must be obtained by the Institutional Review Board/Independent Ethics Committee.
Patients cannot be currently participating in an Alexion-sponsored clinical trial. Patients who have concluded participation in an Alexion-sponsored sebelipase alfa clinical trial are eligible to enroll in this Registry, and enrollment in the Registry will not exclude a patient from enrolling in a future clinical trial.
clinicaltrials@alexion.com1-855-752-2356
Stanford, California 94305, United States
ClinicalTrials@alexion.com
Prague, Central Bohemia 128 00, Czechia
mabarbar@sescam.jccm.es+34 967 59 72 14
Petersburg, Leningradskaya Oblast' 194100, Russia
vlassovnik12@yahoo.com+7 921 905 7485
Moscow, Moscow Oblast 115446, Russia
f.feillet@chu-nancy.fr+33 0624560804
Moscow, Moscow Oblast 119049, Russia
orphancenter@mail.ru+7 916 519 62 43
Moscow, Moscow Oblast 119192, Russia
zharkovamaria@mail.ru+7 9057999137
Moscow, Moscow Oblast 119296, Russia
apotap@mail.ru+7 499 1341582
ClinicalTrials@alexion.com
ClinicalTrials@alexion.com
ClinicalTrials@alexion.com
ClinicalTrials@alexion.com
ClinicalTrials@alexion.com
ClinicalTrials@alexion.com
Chris.Mitrevski@health.nsw.gov.au+61 2 4964 7447
f.feillet@chu-nancy.fr+330624560804
mirondon@unicamp.br+55 19 3521 8554
marcelo.yamamoto@igeim.org.br+55 11 5081 9620 ext. 9630
rocco@hepatogastro.com.br+55 11 99915 8070
mila.baycheva@gmail.com+359887443102
schellev@ualberta.ca+1 780 686 0266
Linda.Hastie@nshealth.ca+1 902 473 4487
+1 519 685 8500
davy.eng@crchudequebec.ulaval.ca+1 418 525 4444 ext. 48584
ivo.baric@kbc-zagreb.hr+385 1 2368318
jana.knourkova@fnol.cz+420 588 443 716
lioara.vanstraelen@chu-lyon.fr+330427856020
cborderon@chu-clermontferrand.fr+33 0473750018
f.feillet@chu-nancy.fr+33 0624560804
patricio.aguiar@edu.ulisboa.pt+351 964 728 526
mabarbar@sescam.jccm.es+34 967 59 72 14
Angelique.hubert@ch-niort.fr+33 0549782428
patricio.aguiar@edu.ulisboa.pt+351 964 728 526
patricio.aguiar@edu.ulisboa.pt+351 964 728 526
isabelle.simoneau@chu-dijon.fr+33 380293332
caroline.chevalier@chu-nantes.fr+33 02 44 76 82 63
mabarbar@sescam.jccm.es+34 967 59 72 14
mabarbar@sescam.jccm.es+34 967 59 72 14
frederike.spengler@uk-essen.de+49 201 723 82232
Adriana.gutierrez@sphincs.de+49 6146 904820
elisabeth.steinhagen-thiessen@charite.de+44 01223274634
lizettag@yahoo.com+30 6944582433
hmilioni@uoi.gr+30 2651099904
mfotoul@otenet.gr+30 694 4949964
ann.loughnane@childrenshealthireland.ie+353 1 8921903
yaelbec@clalit.org.il+972 3 9253663
LiatPr@clalit.org.il+972 6232306
tehilabm@szmc.org.il+972 26666482
irinar@hadassah.org.il+972 528709824
albina.tummolo@policlinico.ba.it+39 3357 306779
v.pecorella@tigem.it+39 0817462673
enrica.epifani@asufc.sanita.fvg.it+39 0432559264
sharongiuliana@gaslini.org+39 01056363777
mferrario@asst-pg23.it+39 035 2673856
domenico.azzolino@policlinico.mi.it+39 0255033558
giulia.massini@unito.it+39 011 3131873
giuseppe.indolfi@meyer.it+39 055 566 2480
chiara.cazzorla@aopd.veneto.it+39 049 8213569 ext. 7462
jchavezmd@gmail.com+52 33 1466 5163
jasad16@yahoo.com.mx+52 44 9189 8445
draalejandraconsuelo@yahoo.com.mx+52 55 52 289 917
n.sons@amsterdamumc.nl+31 205666360
patricio.aguiar@edu.ulisboa.pt+351 964 728 526
olgazevedo@yahoo.com.br+351 916 008 636
patricio.aguiar@edu.ulisboa.pt+351 964 728 526
lavrova26@mail.ru+7 831 436 03 84
hbinomar@kfshrc.edu.sa+966 11 4424988
AniziH7@MNGHA.MED.SA+966 566375166
damjana.nikovski@kclj.si+386 522 3903
ClinicalTrials@alexion.com
ClinicalTrials@alexion.com
ClinicalTrials@alexion.com
ClinicalTrials@alexion.com
liz.morris@addenbrookes.nhs.uk+44 01223 349810 ext. 59810
anaamado.fondo@nhs.net2034483272
mabarbar@sescam.jccm.es+34 967 59 72 14
Michaela.smyth@nca.nhs.uk+44 01612061544
Rachel.Smith148@nhs.net+44 01213339907